Trevi Therapeutics (TRVI) Tops Q3 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Labcorp acquires MLM Medical Labs to expand lab network
• GE Aerospace to acquire Consolidated Precision in $11.75b deal